Oncology is an area that has gained ground in the last three decades in the pharmaceutical industry, due to the increasing incidence of cancer in the world¹ and currently encompasses about 40% of companies². And it keeps growing. For this reason, in addition to investment, there is a need for effective public policies to guarantee patient care and access to these new technologies. With this in mind, GSK has been investing in R&D since 2015 to enhance its portfolio, moving from a pipeline of classic molecules to one based on innovative and transformational therapies.
Considered one of the most innovative, reliable and best performing healthcare companies in the world, GSK brings high quality healthcare products to as many people as possible, through global business, technical and scientific knowledge and the talent of its employees. employees around the world.
In these five years, GSK has made significant advances in research and development of new cancer therapies and has doubled the number of molecules in clinical studies by the company. “With the purpose of offering a transformational portfolio, we foresee, for the next years, the launch of therapies against ovarian, endometrial, multiple myeloma, lung cancer and others”, highlights Deborah Soares, director of Oncology at GSK Farma Brazil.
To expand the pipeline and meet the needs of patients, GSK invests in a collaborative model, through acquisitions and partnerships, which has also been happening in Oncology. According to the executive, “GSK has fifteen molecules in clinical development, some have already been approved, others are in the final stages of studies and some are already being submitted to regulatory agencies”.
In this expansion, the company intends to extend the partnerships made with international biotechnology companies and open the doors to national research institutions, as in the areas of Vaccines and HIV, which has projects developed in collaboration with Fiocruz, Instituto Butantan, Funed , FAPESP and other centers of excellence.
In Brazil alone, GSK is in the process of development and has planned six more clinical studies in oncology, involving approximately 60 institutions with molecules for the treatment of ovarian cancer, multiple myeloma, head and neck and lung cancer.
The company is also investing in research for solid tumors through immuno-oncology. Immunological and therapies based on epigenetics, cell therapy and synthetic lethality are also in the pipeline, which are increasingly gaining ground for promoting tumor cell death through more modern and effective mechanisms.
The medical director of GSK Farma Brasil, Dr. Evelyn Lazaridis, says that “Oncology has shown itself to be increasingly fascinating, not only because of the knowledge and data obtained, but also because of what we still do not know. In this path of research, we are helping to improve and transform the lives of millions, including patients, families and health professionals ”.
1. World Health Organization. Available at: https://www.who.int/cancer/PRGlobocanFinal.pdf?ua=1. Accessed on August 10, 2020.
2. The Economist. Cancer is a curse, but also a growth market for investors. Available at https://www.economist.com/finance-and-economics/2018/02/01/cancer-is-a-curse-but-also-a-growth-market-for-investors. Accessed August 14, 2020.
Source link by https://www.correiobraziliense.com.br/parceiros/gsk/2020/11/4887660-gsk-investe-em-p-d-para-expandir-oncologia-no-mercado-nacional.html
*The article has been translated based on the content of Source link by https://www.correiobraziliense.com.br/parceiros/gsk/2020/11/4887660-gsk-investe-em-p-d-para-expandir-oncologia-no-mercado-nacional.html
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!